Advances in hepatitis C therapies

Bibliography

• Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect 2011;17(2):107-15
   PubMed Web of Science ®Google Scholar
• Hepatitis C. Fact Sheet No. 164. World Health Organization, Geneva, Switzerland. Available from: www.who.int/mediacentre/factsheets/fs164/en/ [Last Accessed 30 March 2015]
   Google Scholar
• Messina JP, Humphreys I, Flaxman A, et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 2015;61(1):77-87
   PubMed Web of Science ®Google Scholar
• Deuffic-Burban S, Mathurin P, Pol S, et al. Impact of hepatitis C triple therapy availability upon the number of patients to be treated and associated costs in France: a model-based analysis. Gut 2012;61(2):290-6
   PubMed Web of Science ®Google Scholar
• Razavi H, Waked I, Sarrazin C, et al. The present and future disease burden of hepatitis C virus (HCV) infection with today’s treatment paradigm. J Viral Hepat 2014;21(Suppl 1):34-59
   PubMed Web of Science ®Google Scholar
• Wedemeyer H, Duberg AS, Buti M, et al. Strategies to manage hepatitis C virus (HCV) disease burden. J Viral Hepat 2014;21(Suppl 1):60-89
   PubMed Web of Science ®Google Scholar
• Swain MG, Lai MY, Shiffman ML, et al. A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin. Gastroenterology 2010;139(5):1593-601
   PubMed Web of Science ®Google Scholar
• Poynard T, McHutchison J, Manns M, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002;122(5):1303-13
   PubMed Web of Science ®Google Scholar
• George SL, Bacon BR, Brunt EM, et al. Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients. Hepatology 2009;49(3):729-38
   PubMed Web of Science ®Google Scholar
• Lee YA, Friedman SL. Reversal, maintenance or progression: what happens to the liver after a virologic cure of hepatitis C? Antiviral Res 2014;107:23-30
   PubMed Web of Science ®Google Scholar
• Lens S, Rincon D, Garcia-Retortillo M, et al. Association between severe portal hypertension and risk of liver decompensation in patients with hepatitis C, regardless of response to antiviral therapy. Clin Gastroenterol Hepatol 2015
   PubMedGoogle Scholar
• Pinzone MR, Zanghi AM, Rapisarda L, et al. Cirrhotic patients are still at risk of developing hepatocellular carcinoma despite Interferon-induced sustained virological response. Eur Rev Med Pharmacol Sci 2014;18(2 Suppl):11-15
   PubMedGoogle Scholar
• van der Meer AJ, Veldt BJ, Feld JJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. Jama 2012;308(24):2584-93
   PubMed Web of Science ®Google Scholar
• Marcellin P, Cheinquer H, Curescu M, et al. High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHESYS cohort confirm results from randomized clinical trials. Hepatology 2012;56(6):2039-50
   PubMed Web of Science ®Google Scholar
• Lindenbach BD, Evans MJ, Syder AJ, et al. Complete replication of hepatitis C virus in cell culture. Science 2005;309(5734):623-6
   PubMed Web of Science ®Google Scholar
• Burgess S, Partovi N, Yoshida EM, et al. A Review of drug interactions with direct-acting antivirals for hepatitis C: Implications for HIV and transplant patients. Ann Pharmacother 2015;49(6):674-87
   PubMed Web of Science ®Google Scholar
• Sovaldi Product information. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002798/WC500160597.pdf [Last Accessed 30 May 2015]
   Google Scholar
• Olysio Product information. Available from: http://ec.europa.eu/health/documents/community-register/2014/20140514128513/anx_128513_en.pdf [Last Accessed 30 May 2015]
   Google Scholar
• Daklinza Product information. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003768/WC500172848.pdf [Last Accessed 30 May 2015]
   Google Scholar
• Harvoni Product information. Available from: http://ec.europa.eu/health/documents/community-register/2014/20141117130011/anx_130011_en.pdf [Last Accessed 30 May 2015]
   Google Scholar
• Viekirax Product information. Available from: http://ec.europa.eu/health/documents/community-register/2015/20150115130406/anx_130406_en.pdf [Last Accessed 30 May 2015]
   Google Scholar
• Exviera Product information. Available from: http://ec.europa.eu/health/documents/community-register/2015/20150115130446/anx_130446_en.pdf [Last Accessed 30 May 2015]
   Google Scholar
• AASLD-IDSA. Recommendations for Testing, Managing, and Treating Hepatitis C. 2015. Available from: http://www.hcvguidelines.org/full-report-view
   Google Scholar
• Gane EJ, Stedman CA, Hyland RH, et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 2013;368:34-44
   PubMed Web of Science ®Google Scholar
• Lalazeri J, Nelson D, Hyland R, et al. Once-daily sofosbuvir plus ribavirin given for 12 or 24 weeks in treatment-naïve patients with HCV: the QUANTUM study. J Hepatol 2013;58(Suppl 1):S346
   Google Scholar
• Osinusi A, Meissner EG, Lee YJ, et al. Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial. Jama 2013;310(8):804-11
   PubMed Web of Science ®Google Scholar
• Afdhal N, Everson GT, Calleja JL, et al. Effect of long term viral suppression with sofosbuvir plus ribavirin on hepatic venous pressure gradient in HCV-infected patients with cirrhosis and portal hypertension. J Hepatol 2015;62:S269
   PubMed Web of Science ®Google Scholar
• Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet 2014;384(9956):1756-65
   PubMed Web of Science ®Google Scholar
• Jensen DM, O’Leary JG, Pockros PJ, et al. Safety and efficacy of sofosbuvir-containing regimens for hepatitis C: Real-World experience in a diverse, longitudinal observational cohort. Hepatology 2014;60:219A
   Web of Science ®Google Scholar
• Dieterich D, Bacon BR, Flamm SL, et al. Evaluation of sofosbuvir and simeprevir-based regimens in the TRIO network: academic and community treatment of a real-world, heterogeneous population. Hepatology 2014;60:220A
   Web of Science ®Google Scholar
• Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014;370(20):1889-98
   PubMed Web of Science ®Google Scholar
• Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014;370(16):1483-93
   PubMed Web of Science ®Google Scholar
• Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014;370(20):1879-88
   PubMed Web of Science ®Google Scholar
• Reddy KR, Bourlière M, Sulkowski M, et al. Ledipasvir and sofosbuvir in patients with genotype 1 HCV and compensated cirrhosis: an integrated safety and efficacy analysis. Hepatology 2015;62(1):79-86
   PubMed Web of Science ®Google Scholar
• Flamm SL, Everson GT, Charlton M, et al. Ledipasvir/sofosbuvir with ribavirin for the treatment of HCV in patients with decompensated cirrhosis: preliminary results of a prospective, multicenter study. Hepatology 2014;60
   Google Scholar
• Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014;370(3):211-21
   PubMed Web of Science ®Google Scholar
• Poordad F, Schiff ER, Vierling JM, et al. Daclatasvir, sofosbuvir, and ribavirin combination for HCV patients with advanced cirrhosis or posttransplant recurrence: Phase 3 ALLY-1 study. J Hepatol 2015;62:S261
   Web of Science ®Google Scholar
• Feld JJ, Kowdley KV, Coakley E, et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014;370(17):1594-603
   PubMed Web of Science ®Google Scholar
• Ferenci P, Bernstein D, Lalezari J, et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med 2014;370(21):1983-92
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Jacobson IM, Baykal T, et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014;370(17):1604-14
   PubMed Web of Science ®Google Scholar
• Andreone P, Colombo MG, Enejosa JV, et al. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. Gastroenterology 2014;147(2):359-65
   PubMed Web of Science ®Google Scholar
• Poordad F, Hezode C, Trinh R, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 2014;370(21):1973-82
   PubMed Web of Science ®Google Scholar
• Sulkowski M, Hezode C, Gerstoft J, et al. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial. Lancet 2015;385(9973):1087-97
   PubMed Web of Science ®Google Scholar
• Lawitz E, Gane E, Pearlman B, et al. Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial. Lancet 2015;385(9973):1075-86
   PubMed Web of Science ®Google Scholar
• Poordad F, Sievert W, Mollison L, et al. Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection. Jama 2015;313(17):1728-35
   PubMed Web of Science ®Google Scholar
• Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013;368(20):1878-87
   PubMed Web of Science ®Google Scholar
• Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013;368(20):1867-77
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Dusheiko GM, Salupere R, et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med 2014;370(21):1993-2001
   PubMed Web of Science ®Google Scholar
• Foster GR, Pianko S, Cooper C, et al. Sofosbuvir + peginterferon/ribavirin for 12 weeks vs sofosbuvir + ribavirin for 16 or 24 weeks in genotype 3 HCV infected patients and treatment-experienced cirrhotic patients with genotype 2 HCV: the boson study. J Hepatol 2015;62:S259
   Google Scholar
• Nelson DR, Cooper JN, Lalezari JP, et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology 2015;61(4):1127-35
   PubMed Web of Science ®Google Scholar
• Hezode C, De Ledinghen V, Fontaine H, et al. Daclatasvir plus sofosbuvir with or without ribavirin in patients with HCV genotype 3 infection: interim analysis of a French multicenter compassionate use program. J Hepatol 2015;62:S265
   Google Scholar
• Gane EJ, Hyland RH, An D, et al. Sofosbuvir/ledipasvir fixed dose combination is safe and effective in difficult-to-treat populations including genotype-3 patients, decompensated genotype-1 patients, and genotype-1 patients with prior sofosbuvir treatment experience. J Hepatol 2014;60(Suppl 1):S3
   Google Scholar
• Lawitz E, Poordad F, Brainard DM, et al. Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis. Hepatology 2015;61(3):769-75
   PubMed Web of Science ®Google Scholar
• Ruane PJ, Ain D, Stryker R, et al. Sofosbuvir plus ribavirin for the treatment of chronic genotype 4 hepatitis C virus infection in patients of Egyptian ancestry. J Hepatol 2015;62(5):1040-6
   PubMed Web of Science ®Google Scholar
• Kapoor R, Kohli A, Sidharthan S, et al. All oral treatment for genotype 4 chronic Hepatitis C Infection with sofosbuvir and ledipasvir: Interim Results from the NIAID SYNERGY Trial. Hepatology 2014;60:321A
   Web of Science ®Google Scholar
• Moreno C, Hezode C, Marcellin P, et al. Efficacy and safety of simeprevir with PegIFN/ribavirin in naive or experienced patients infected with chronic HCV genotype 4. J Hepatol 2015;62(5):1047-55
   PubMed Web of Science ®Google Scholar
• Hezode C, Hirschfield GM, Ghesquiere W, et al. Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study. Gut 2015;64(6):948-56
   PubMed Web of Science ®Google Scholar
• Pol S, Reddy KR, Baykal T, et al. Interferon-free regimens of ombitasvir and ABT-450/r with or without ribavirin in patients with HCV genotype 4 infection: PEARL-I study results. Hepatology 2014;60:1129A
   Web of Science ®Google Scholar
• Reddy KR, Bourliere M, Sulkowski M, et al. Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: an integrated safety and efficacy analysis. Hepatology 2015;62(1):79-86
   PubMed Web of Science ®Google Scholar
• Forns X, Gordon SC, Zuckerman E, et al. Grazoprevir/Elbasvir plus Ribavirin For chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent. J Hepatol 2015
   Web of Science ®Google Scholar
• Wyles D, Pockros P, Morelli G, et al. Ledipasvir-sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimens. Hepatology 2015;61(6):1793-7
   PubMed Web of Science ®Google Scholar
• Lawitz E, Flamm S, Yang JC, et al. Retreatment of patients WHO failed 8 or 12 weeks of ledipasvir/sofosbuvir-based regimens with ledipasvir/sofosbuvir for 24 weeks. J Hepatol 2015;62:S192
   Web of Science ®Google Scholar
• EASL Recommendations on treatment of hepatitis C 2015. J Hepatol 2015.63(1):199-236 Available from: http://dx.doi.org/10.1016/j.jhep.2015.03.025
   Google Scholar
• Townsend KS, Osinusi A, Nelson AK, et al. High efficacy of sofosbuvir/ledipasvir for the treatment of HCV genotype 1 in patients coinfected with HIV on or off antiretroviral therapy: Results from the NIAID ERADICATE Trial. Hepatology 2014;60:240A
   Web of Science ®Google Scholar
• Sulkowski MS, Eron JJ, Wyles D, et al. Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial. Jama 2015;313(12):1223-31
   PubMed Web of Science ®Google Scholar
• Wyles D, Ruane P, Sulkowski M, et al. Daclatasvir in combination with sofosbuvir for HIV/HCV coinfection: ALLY-2 study. In: CROI. Seattle, WA; 2015
   Google Scholar
• Forman LM, Lewis JD, Berlin JA, et al. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002;122(4):889-96
   PubMed Web of Science ®Google Scholar
• Crespo G, Marino Z, Navasa M, Forns X. Viral hepatitis in liver transplantation. Gastroenterology 2012;142(6):1373-83
   PubMed Web of Science ®Google Scholar
• Curry MP, Forns X, Chung RT, et al. Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study. Gastroenterology 2015;148(1):100-7
   PubMed Web of Science ®Google Scholar
• Borentain P, Colson P, Darque A, Gerolami R. Optimal duration of pre-liver transplantation anti-hepatitis C virus treatment with direct-acting agent sofosbuvir. Liver Int 2015;35(6):1776
   PubMed Web of Science ®Google Scholar
• Donato M, Monico S, Malinverno F, et al. Bridging all oral DAA therapy from wait time to post-liver transplant to improve HCV eradication? Liver Int 2015;35(1):1-4
   PubMed Web of Science ®Google Scholar
• Stine JG, Intagliata N, Shah NL, et al. Hepatic decompensation likely attributable to simeprevir in patients with advanced cirrhosis. Dig Dis Sci 2014;60(4):1031-5
   PubMed Web of Science ®Google Scholar
• Saxena V, Terrault NA. Hepatitis C direct antiviral drugs and hepatic decompensation in patients with advanced cirrhosis: culprit or innocent bystander? Dig Dis Sci 2015;60(4):806-9
   PubMed Web of Science ®Google Scholar
• Fujii Y, Uchida Y, Mochida S. Drug-induced immunoallergic hepatitis during combination therapy with daclatasvir and asunaprevir. Hepatology 2015;61(1):400-1
   PubMed Web of Science ®Google Scholar
• Ruiz I, Feray C, Pawlotsky JM, Hezode C. Patient with decompensated hepatitis C virus-related cirrhosis delisted for liver transplantation after successful sofosbuvir-based treatment. Liver Transpl 2015;21(3):408-9
   PubMed Web of Science ®Google Scholar
• Charlton M, Gane E, Manns MP, et al. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. Gastroenterology 2015;148(1):108-17
   PubMed Web of Science ®Google Scholar
• Forns X, Charlton M, Denning J, et al. Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation. Hepatology 2014;61(5):1485-94
   Web of Science ®Google Scholar
• Kwo PY, Mantry PS, Coakley E, et al. An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med 2014;371(25):2375-82
   PubMed Web of Science ®Google Scholar
• Samuel D, Manns M, Forns X, et al. Ledipasvir/sofosbuvir with ribavirin is safe in >600 decompensated and post liver transplantation patients with HCV infection: an integrated safety analysis of the solar 1 and solar 2 trials. J Hepatol 2015;62:S620
   Google Scholar
• Brown Jr R, Reddy KR, O’Leary JG, et al. Safety and efficacy of new DAA-based therapy for hepaittis C post-transplant: Interval results from the HCV-TARGET longitudinal, observational study. Hepatology 2014;60:S1297
   Google Scholar
• Pungpapong S, Werner KT, Aqel B, et al. Multicenter experience using sofosbuvir and simeprevir with/without ribavirin to treat HCV genotype 1 after liver transplantation. Hepatology 2014;60:210A
   Google Scholar
• Leroy V, Dumortier J, Coilly A, et al. High rates of virological response and major clinical improvement during sofosbuvir and daclatasvir-based regimens for the treatment of fibrosing cholestatic HCV-recurrence after liver transplantation: The ANRS CO23 CUPILT study. Hepatology 2014;60:207A
   Web of Science ®Google Scholar
• Coilly A, Fougerou C, De Ledinghen V, et al. The association of sofosbuvir and daclatasvir for treating severe recurrence of hcv infection after liver transplantation: results from a large French prospective multicentric ANRS CO23 cupilt cohort. J Hepatol 2015;62
   Google Scholar
• Zimner-Rapuch S, Janus N, Deray G, Launay-Vacher V. New therapies for hepatitis C: considerations in patients with renal impairment. Drugs 2014;74(12):1307-13
   PubMed Web of Science ®Google Scholar
• Xia Y, Friedmann P, Yaffe H, et al. Effect of HCV, HIV and coinfection in kidney transplant recipients: mate kidney analyses. Am J Transplant 2014;14(9):2037-47
   PubMed Web of Science ®Google Scholar
• Baid-Agrawal S, Pascual M, Moradpour D, et al. Hepatitis C virus infection and kidney transplantation in 2014: what’s new? Am J Transplant 2014;14(10):2206-20
   PubMed Web of Science ®Google Scholar
• Rostami Z, Nourbala MH, Alavian SM, et al. The impact of Hepatitis C virus infection on kidney transplantation outcomes: A systematic review of 18 observational studies: The impact of HCV on renal transplantation. Hepat Mon 2011;11(4):247-54
   PubMed Web of Science ®Google Scholar
• Fabrizi F, Martin P, Dixit V, Messa P. Meta-analysis of observational studies: hepatitis C and survival after renal transplant. J Viral Hepat 2014;21(5):314-24
   PubMed Web of Science ®Google Scholar
• Terrault NA, Stock PG. Management of hepatitis C in kidney transplant patients: on the cusp of change. Am J Transplant 2014;14(9):1955-7
   PubMed Web of Science ®Google Scholar
• Saxena V, Koraishy FM, Sise M, et al. Safety and efficacy of sofosbuvir-containing regimens in hepatitis C infected patients with reduced renal function: real-World experience from HCV-target. J Hepatol 2015;62:S267
   Google Scholar
• Pockros PJ, Reddy KR, Mantry PS, et al. Safety of ombitasvir/paritaprevir/ritonavir plus dasabuvir for treating HCV GT1 infection in patients with severe renal impairment or end-stage renal disease: the RUBY-I study. J Hepatol 2015;62:S257
   PubMed Web of Science ®Google Scholar
• Roth D, Nelson D, Bruchfeld A, et al. C-surfer: grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease. J Hepatol 2015;62:S263
   Google Scholar
• Huard G, Kim B, Patel A, et al. Early safety and efficacy profiles of renal transplant recipients with chronic hepatitis C treated with sofosbuvir and ribavirin. Hepatology 2014;60:540A
   Web of Science ®Google Scholar
• Gordon FD, Kosinski AL, Coombs SJ, et al. Sofosbuvir + simeprevir is safe in liver transplant recipients. Hepatology 2014;60:543A
   Web of Science ®Google Scholar